Moderna officer Stephen Hoge proposes $8.37M sale
Stephen Hoge also listed three prior sales dated July 15, September 14 and September 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Moderna, Inc. officer Stephen Hoge reported a proposed sale of 39,224 common shares, with an approximate sale date of October 14, 2026, through Fidelity Brokerage Services LLC. The stated aggregate market value is $8,373,519.16, and NASDAQ is listed as the exchange. The shares are identified as acquired from the issuer through a stock option exercise for cash on October 14, 2026. Daniel Tucci signed as a duly authorized representative of Fidelity Brokerage Services LLC and as attorney-in-fact for Stephen Hoge.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
attorney-in-fact regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior MRNA sales did Stephen Hoge report?
AI-generated analysis. How Rhea-AI works. Not financial advice.